AGIOS PHARMACEUTICALS INC. - COMMON STOCK

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

16 سبتمبر 2022 06:41:44 بحسب Nasdaq GlobeNewswire

Agios to Participate in September Investor Conferences

24 أغسطس 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

18 أغسطس 2022 18:35:00 بحسب Nasdaq GlobeNewswire

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

15 أغسطس 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

11 أغسطس 2022 18:35:00 بحسب Nasdaq GlobeNewswire

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

08 أغسطس 2022 18:36:08 بحسب Nasdaq GlobeNewswire

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

04 أغسطس 2022 07:00:02 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

14 يوليو 2022 07:00:00 بحسب Nasdaq GlobeNewswire

Agios Appoints Brian Goff as Chief Executive Officer

12 يوليو 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

10 يونيو 2022 10:30:00 بحسب Nasdaq GlobeNewswire

Agios Announces Evolution of Research Organization

16 مايو 2022 16:15:00 بحسب Nasdaq GlobeNewswire

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

12 مايو 2022 10:00:00 بحسب Nasdaq GlobeNewswire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

10 مايو 2022 07:00:05 بحسب Nasdaq GlobeNewswire

Agios Reports Business Highlights and First Quarter 2022 Financial Results

05 مايو 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of First Quarter 2022 Financial Results on May 5, 2022

21 أبريل 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Agios Announces Publication of Phase 3 ACTIVATE Study in New England Journal of Medicine Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

14 أبريل 2022 08:34:52 بحسب Nasdaq GlobeNewswire

Agios to Participate in March Investor Conferences

28 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire

Agios Reports Fourth Quarter and Full Year 2021 Financial Results

24 فبراير 2022 07:00:03 بحسب Nasdaq GlobeNewswire

Agios Announces FDA Approval of PYRUKYND® (mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

17 فبراير 2022 15:41:11 بحسب Nasdaq GlobeNewswire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2021 Financial Results on Feb. 24, 2022

10 فبراير 2022 07:00:01 بحسب Nasdaq GlobeNewswire